CVM
CVMCIK 0000725363
Size data not yet pulled for this ticker — check back in a moment.
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (PURR 10-K) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade CVM commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
CEL-SCI files S-1/A for best-efforts offering of up to 4.89M shares at $3.07, raising up to $15M gross
7 material changes detected. Sign up free to read the summary.
Latest financial statements
From 10-Q filed Aug 14, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Statements of Operations (Unaudited)
| Description | Nine months ended June 30, 2026 | Nine months ended June 30, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | 11,094,085 | 12,184,276 |
| General & administrative | 5,158,015 | 6,592,128 |
| Total operating expenses | 16,252,100 | 18,776,404 |
| Operating loss | (16,252,100) | (18,776,404) |
| Interest expense, net | (315,514) | (520,439) |
| Other expense | (35,108) | (13,312) |
| Net loss | (16,602,722) | (19,310,155) |
| Net loss available to common shareholders | (16,602,722) | (19,310,155) |
| Net loss per common share basic and diluted | (1.76) | (6.34) |
| Weighted average common shares outstanding basic and diluted | 9,423,006 | 3,046,400 |
Condensed Balance Sheets
| Description | June 30, 2026 (UNAUDITED) | September 30, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | 6,527,381 | 10,953,460 |
| Prepaid expenses | 702,018 | 332,301 |
| Supplies used for R&D and manufacturing | 266,763 | 303,282 |
| Deposits | 7,805 | 7,085 |
| Total current assets | 7,503,967 | 11,596,128 |
| Finance lease right-of-use assets | 4,196,553 | 5,548,186 |
| Operating lease right-of-use assets | 1,442,285 | 1,274,780 |
| Property and equipment, net | 4,578,795 | 6,079,295 |
| Patent costs, net | 69,688 | 119,856 |
| Deposits | 2,319,101 | 2,319,101 |
| Supplies used for R&D and manufacturing | 1,245,027 | 1,218,402 |
| Total assets | 21,355,416 | 28,155,748 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current Liabilities: | ||
| Accounts payable | 1,023,200 | 1,061,351 |
| Accrued expenses | 462,121 | 711,820 |
| Due to employees | 890,404 | 916,588 |
| Finance lease obligation, current portion | 2,487,377 | 2,273,797 |
| Operating lease obligation, current portion | 216,569 | 166,990 |
| Total current liabilities | 5,079,671 | 5,130,546 |
| Finance lease liabilities, net of current portion | 3,784,436 | 5,684,127 |
| Operating lease liabilities, net of current portion | 1,410,521 | 1,258,990 |
| Other liabilities | 125,000 | 125,000 |
| Total liabilities | 10,399,628 | 12,198,663 |
| Commitments and contingencies (Note E) | ||
| STOCKHOLDERS’ EQUITY | ||
| Preferred stock, $0.01 par value; 200,000 shares authorized; 0 shares issued and outstanding | - | - |
| Common stock, $0.01 par value; 600,000,000 shares authorized; 17,588,653 and 8,015,701 shares issued and outstanding at June 30, 2026 and September 30, 2025, respectively | 173,077 | 80,157 |
| Additional paid-in capital | 566,808,349 | 555,299,844 |
| Accumulated deficit | (556,025,638) | (539,422,916) |
| Total stockholders’ equity | 10,955,788 | 15,957,085 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | 21,355,416 | 28,155,748 |
Condensed Statements of Cash Flows (Unaudited)
| Description | Nine months ended June 30, 2026 | Nine months ended June 30, 2025 |
|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | (16,602,722) | (19,310,155) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 2,867,193 | 2,924,303 |
| Non-cash lease expense, net of lease payments | 33,605 | (2,970) |
| Share-based payments for services | 271,159 | 587,285 |
| Equity based compensation | 1,348,750 | 1,470,491 |
| Common stock contributed to 401(k) plan | 179,606 | 164,510 |
| Shares issued for settlement of clinical development costs | 479,790 | 350,885 |
| Loss on patent impairment | 35,108 | 13,312 |
| (Increase)/decrease in assets: | ||
| Prepaid expenses | (370,182) | (13,874) |
| Supplies used for R&D and manufacturing | 9,894 | 622,831 |
| Deposits | (720) | (4,000) |
| Increase/(decrease) in liabilities: | ||
| Accounts payable | (41,318) | 2,444 |
| Accrued expenses | (259,699) | (60,490) |
| Due to employees | (26,184) | 806,214 |
| Net cash used in operating activities | (12,075,720) | (12,449,214) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchases of property and equipment | - | (32,954) |
| Net cash used in investing activities | - | (32,954) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from issuance of common stock and pre-funded warrants | 9,700,000 | 12,560,300 |
| Payments of stock issuance costs | (1,093,620) | (1,531,832) |
| Proceeds from the purchase of stock by officers and directors | 729,000 | - |
| Proceeds from notes payable | - | 350,000 |
| Payments of notes payable | - | (350,000) |
| Payments on obligations under finance leases | (1,685,739) | (1,491,617) |
| Net cash provided by financing activities | 7,649,641 | 9,536,851 |
| NET DECREASE IN CASH AND CASH EQUIVALENTS | (4,426,079) | (2,945,317) |
| CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD | 10,953,460 | 4,738,173 |
| CASH AND CASH EQUIVALENTS, END OF PERIOD | 6,527,381 | 1,792,856 |
Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗